2014 – Virobay completes $8 million Series B preferred stock financing more
2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more
2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more
2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more
2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more
Robert Booth was the driving force behind the creation of Virobay in 2006. While he was the Executive Chairman of Virobay, Inc. from 2006 to 2010, he concurrently served as an Operating Partner and Senior Advisor at TPG Biotech, a venture capital company.
Previously, he was Chief Scientific Officer at Celera Genomics, responsible for integrating and leading Celera's therapeutic discovery and development activities. The therapeutic areas pursued by Celera included oncology, autoimmunity, respiratory diseases and thrombosis.
Robert also served in a series of executive positions at Roche for over 13 years, including Senior Vice President responsible for research and early development in the therapeutic areas of inflammation, autoimmunity, virology, respiratory diseases, transplantation and bone disease products. Robert was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche. During his time at Roche, Robert managed R&D organizations in both the US and Europe.
Robert serves on the board of Pharmacyclics Inc. He is a board member of Glialogix, Inc and he is a board observer and Chairman of the Science Advisory Board of Galleon Pharmaceuticals. He is also a member of the Science Advisory Boards of ShangPharma ChemPartner and Elcelyx. Additionally, he serves as a consultant to a number of biotech and venture capital groups.
Robert obtained his B.Sc. and Ph.D. from the University of London in the field of biochemistry.
Dan joined Alta immediately following the firmís founding in 1996, and was a co-founder of the Alta BioPharma effort.
Dan focuses on investments in biopharmaceutical products and therapeutics. He has been directly involved in the funding and development of over 25 life sciences companies. Dan is currently on the board of directors of a number of companies, including Alba Therapeutics, DiscoveRx, Esperion Therapeutics, Lithera, Prolacta Bioscience and ViroBay. In addition, he led Altaís investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical.
Prior to joining Alta, he was a senior investment banker at Montgomery Securities, focusing on life sciences companies. Dan is also a member of The President's Council of the Gladstone Institutes.
He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.
Jeff Bird focuses on healthcare, including biotechnology and medical devices.†
He is currently a board member at†Verinata Health†(noninvasive prenatal diagnosis),†Drais Pharmaceuticals†(oncology therapeutics),†Horizon Pharma, Inc.†(novel fixed dose drug combinations),†NuGen Technologies (research reagents),†Portola Pharmaceuticals†(a spin-out of Cor/Millennium focused on cardiovascular therapeutics),†Restoration Robotics†(aesthetic surgery devices),†Threshold Pharmaceuticals†(oncology therapeutics, NASDAQ: THLD), and†ViroBay, Inc.†(pain and inflammatory therapeutics). He also represents the firmís investments in†Acceleron Pharmaceuticals (metabolic therapeutics),†Ameritox†(pain therapeutic drug monitoring) and†Pacific Biosciences†(DNA sequencing).†
Jeff was formerly a director at Akarx Inc., (acquired by MGI Pharma in 2008), BARRX Medical, Inc. (acquired by Covidien in 2012), Idun Pharmaceuticals, (acquired by Pfizer in 2005), Roxro Pharma (acquired by Daiichi-Sankyo in 2010), and Xoft, Inc. (acquired by iCAD in 2010).†
Jeff was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the US and Europe.†
Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.
Heather Preston, MD, is Managing Director of TPG Biotech. Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates.
Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. After leaving Oxford, she completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. She completed her training in Internal Medicine at the Massachusetts General Hospital and then she sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. After leaving academic medicine, she spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies.
Dr. Preston co-founded Virobay Inc. She currently serves on the boards of Albireo, Alder Biotherapeutics, Aptalis Pharma, Conventus Orthopaedics, Otonomy and Virobay. Previously she has served on the boards of VLST and Elevation Pharmaceuticals (acquired by Sunovion in September 2012).
Thomas J. Dietz, Ph.D. is Chairman and CEO of Waypoint Holdings, LLC, a diversified financial holdings and services company. Dr. Dietz was co-CEO then CEO, and a Director of Pacific Growth Equities, LLC, a San Francisco-based Investment Bank and Institutional Brokerage Firm from 2004 to 2009, when the Firm was acquired by Wedbush Securities. Dr. Dietz served as Head of the Investment Banking Division at Wedbush until November 2010. Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the Companyís Director of Equities Research and was an award winning Biotechnology and Biopharmaceutical Analyst. Dr. Dietz joined Pacific Growth in 1993. Previously, Dr. Dietz was a member of the Research Faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz currently serves as Chairman of Galleon Pharmaceuticals, Inc. and Director of both Glialogix, Inc. and Transcept Pharmaceuticals, Inc. as well as on the board of trustees of the West Bay Region of the Sutter Health system that includes California Pacific Medical Center, San Francisco.
Dr. Dietz holds a Ph.D. in Molecular Biology and Biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-doctoral Fellow.